地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:18372041646
邮箱:sales@amyjet.com
![]()
艾美捷科技代理Medix Biochemica品牌。
Medix Biochemica是重要的体外诊断原材料供应商,生产和供应高质量的抗体、抗原和其他关键的IVD原材料,涵盖免疫测定、临床化学和分子诊断等细分市场。Medix Biochemica拥有5000多种产品,可提供超过95%的最常见试剂,用于检测开发、生产和验证。Medix Biochemica提供高质量的单克隆抗体,也可以提供定制OEM服务,让抗体生产变得轻松。该工艺包括通过细胞系驯化、支原体检测、生产优化和验证进行评估和优化。
Medix Biochemica产品包括:
(1)抗体/抗原/酶:包含5000多种产品,涵盖300多种指标;
(2)MedixMDx:分子生物学应用原料;
(3)生物样本和生物材料。
< " data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Medix Biochemica品牌"> 艾美捷科技代理Medix Biochemica品牌
艾美捷科技代理Chemtrade品牌佐剂产品。
Chemtrade专业生产氢氧化铝胶佐剂,用于细菌疫苗、狂犬病疫苗、HPV疫苗、肺炎球菌疫苗、流感疫苗产品等。Chemtrade氢氧化铝胶佐剂主要用于动物疫苗的生产中,作为佐剂与疫苗抗原混合使用。其使用方法通常是将佐剂与抗原以一定比例混合均匀,然后注入动物体内以产生免疫效果。
Chemtrade佐剂特点包括:
(1)粒径小:Chemtrade氢氧化铝胶佐剂的粒径较小,这使得其具有更大的表面积和更强的吸附能力。这一特点使得佐剂能够更有效地与疫苗抗原结合,提高疫苗的免疫效果。
(2)高吸附能力:由于粒径小和表面积大,Chemtrade氢氧化铝胶佐剂能够吸附更多的抗原,从而增强疫苗的免疫原性和稳定性。
(3)低副反应:Chemtrade氢氧化铝胶佐剂在使用过程中表现出较低的副反应,对动物体更为友好,减少了疫苗接种后的不良反应。
(4)品质保障:作为进口佐剂,Chemtrade氢氧化铝胶佐剂经过严格的质检和认证,确保其符合国际标准和要求。同时,国内代理商如河南通商等也提供了稳定的产品供应和优质的服务。

艾美捷科技代理StressMarq品牌。
StressMarq公司为生命科学和药物发现/生物制药市场生产高质量、尖端的研究产品。StressMarq公司产品包括:用于神经退行性疾病研究的原纤维、寡聚体和单体蛋白质制剂,包括α突触
核蛋白、tau蛋白、β淀粉样蛋白、SOD1蛋白和TTR蛋白等。StressMarq的战略重点是协助研究人员研究阿尔茨海默氏症、帕金森氏症和其他神经退行性疾病。除了专注于神经退行性疾病研
究的蛋白质外,StressMarq公司多样化的产品组合抗体、试剂盒、小分子和其他蛋白质,也广泛应用于神经科学、癌症研究和细胞信号传导等一系列生命科学领域。产品包括:
(1)抗体:提供数百种经过高度验证的单克隆和多克隆抗体.
(2)抗体偶联物:从一系列荧光团、蛋白质或酶偶联物中进行选择。
(3)检测试剂盒:浏览我们精选的细胞信号传导、细胞和氧化应激研究试剂盒。
(4)蛋白质:专门研究α突触核蛋白、tau和淀粉样蛋白β的纤维形式、寡聚形式和单体。
(5)小分子:抑制剂、拮抗剂、激动剂、激活剂和配体。
< " data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理StressMarq品牌"> 艾美捷科技代理StressMarq品牌
艾美捷科技代理艾美捷科技代理Apollo Scientific化学试剂。
Apollo Scientific Ltd 是一家总部位于英国的公司,专注于为全球的研究和开发(R&D)市场提供高质量的化学试剂和中间体。公司成立于1996年,致力于为制药、生物技术、农业化学和材料科学等领域的研究人员提供化学产品。化学试剂和中间体:提供超过10万种化学试剂和中间体,涵盖有机化学、无机化学和材料科学等领域。包括杂环化合物、氨基酸衍生物、手性化合物和催化剂等。Apollo Scientific公司特色产品包括:氟化、杂环、有机物、无机物等化学产品,如:HEPES、毛地黄皂甙、DTE 二硫代赤藓醇等。
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Apollo Scientific化学试剂"> 艾美捷科技代理Apollo Scientific化学试剂

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Industria Chimica Emiliana (ICE) 品牌。
Industria Chimica Emiliana (ICE) 是一家意大利公司,专注于为制药、化妆品、食品和工业领域提供高质量的天然和合成表面活性剂、乳化剂、润湿剂和其他特种化学品。公司成立于 1947 年,总部位于意大利雷焦艾米利亚(Reggio Emilia),凭借其创新的产品、严格的质量控制和可持续发展理念,已成为全球特种化学品行业的领先企业之一。意大利 Industria Chimica Emiliana (ICE)还致力于胆汁衍生产品的制造,经典产品:脱氧胆酸钠,可提供 GMP 级别。核心业务领域:
(1)表面活性剂和乳化剂:ICE 提供多种天然和合成表面活性剂,包括阴离子、非离子、阳离子和两性表面活性剂。这些产品广泛应用于制药、化妆品、食品和工业领域,用于乳化、润湿、分散和清洁等用途。
(2)制药和化妆品原料:公司为制药和化妆品行业提供高质量的原料,如乳化剂、增稠剂、稳定剂和润湿剂。这些原料用于制造乳膏、乳液、凝胶、洗发水、护肤品和其他个人护理产品。
(3)食品添加剂:ICE 提供用于食品工业的乳化剂、稳定剂和润湿剂,支持食品加工、烘焙、乳制品和饮料生产。
(4)工业化学品:公司为工业应用提供特种化学品,如金属加工液、清洁剂、涂料和油墨添加剂。
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Industria Chimica Emiliana (ICE) 品牌"> 艾美捷科技代理Industria Chimica Emiliana (ICE) 品牌

艾美捷科技代理Chemtrade品牌佐剂产品。
Chemtrade专业生产氢氧化铝胶佐剂,用于细菌疫苗、狂犬病疫苗、HPV疫苗、肺炎球菌疫苗、流感疫苗产品等。Chemtrade氢氧化铝胶佐剂主要用于动物疫苗的生产中,作为佐剂与疫苗抗原混合使用。其使用方法通常是将佐剂与抗原以一定比例混合均匀,然后注入动物体内以产生免疫效果。
Chemtrade佐剂特点包括:
(1)粒径小:Chemtrade氢氧化铝胶佐剂的粒径较小,这使得其具有更大的表面积和更强的吸附能力。这一特点使得佐剂能够更有效地与疫苗抗原结合,提高疫苗的免疫效果。
(2)高吸附能力:由于粒径小和表面积大,Chemtrade氢氧化铝胶佐剂能够吸附更多的抗原,从而增强疫苗的免疫原性和稳定性。
(3)低副反应:Chemtrade氢氧化铝胶佐剂在使用过程中表现出较低的副反应,对动物体更为友好,减少了疫苗接种后的不良反应。
(4)品质保障:作为进口佐剂,Chemtrade氢氧化铝胶佐剂经过严格的质检和认证,确保其符合国际标准和要求。同时,国内代理商如河南通商等也提供了稳定的产品供应和优质的服务。
<艾美捷科技代理Celartia品牌全系列产品
Celartia Inc.是一家美国制造商,专注于生产技术先进的专用细胞培养产品。Celartia的旗舰产品是Petaka G3封闭式细胞培养盒。其采用高氧气扩散率的共聚物材料(PMMA)制成。其技术原理包括:
● 气体自调节:无需外部CO₂或湿度控制,通过材料特性自动维持培养器内最佳氧浓度,避免过量供氧。
● 防污染设计:全密封结构,无盖、无泄漏,显著降低污染风险。
● 高效空间利用:仅需 20–24ml培养基即可提供约150cm²的生长面积,相当于体积的15倍。
Petaka G3三款型号产品详情:
| 型号 | Petaka®G3 FLAT | Petaka®G3 HOT | Petaka®G3 LOT |
| 产品应用 | 用于非贴壁细胞(悬浮活细胞) | 用于贴壁细胞(附着型活细胞) | 用于贴壁细胞(附着型活细胞) |
| 产品描述 | 自调节、自给自足的细胞培养生物反应器,可控制氧气、CO₂、pH值和蒸发,无需手套箱、三气培养箱或气罐。 Petaka®G3 FLAT 能在环境温度下维持培养基环境稳定,并使细胞长期保持存活。 | 自调节、自给式细胞培养生物反应器:通过更高氧气交换能力 控制氧气、CO₂、pH 值及蒸发,无需手套箱、三气培养箱或气罐。 环境温度稳定性:在常温下维持培养基环境稳定,尤其适用于高生理耗氧的细胞类型。 | 自调节、自给式细胞培养生物反应器:控制氧气、CO₂、pH 值及蒸发,无需手套箱、三气培养箱或气罐。 环境温度稳定性与细胞活性维持: 在常温下维持培养基环境稳定,并使细胞长期保持存活。 |
| 主要优势 | 适用于非贴壁细胞的生理状态培养。 无需冷冻保存即可进行非贴壁细胞的运输。 | 专为需高氧交换的贴壁细胞提供生理级培养条件。 | 专为贴壁细胞提供 生理级培养条件 实现无需冷冻保存的贴壁细胞运输 |
| 氧气传输 | 悬浮优化 | 高氧交换 | 标准氧传输 |
| 适配细胞类型 | 淋巴细胞/干细胞/杂交瘤 | 软骨/成骨/内皮细胞 | 常规贴壁细胞 |
| 核心场景 | 悬浮细胞常温稳定化处理 | 高耗氧组织工程研究 | 常温运输及基础培养 |

▍产品列表
| 品名 | 货号 | 分类 | 规格 |
| Petaka®G3 HOT, box 25 pcs | HTPTK25 | 1. Petaka CELL CULTURE, PetakaG3 HOT. | 25 pcs box. Sterile (SAL 10-6) |
| Petaka®G3 HOT, box 300 pcs | HTPTK300 | 1. Petaka CELL CULTURE. | 25 pcs box. Sterile (SAL 10-6) |
| Petaka®G3 FLAT, box 25 pcs | FLPTK25 | 1. Petaka CELL CULTURE, 2. Petaka cell shipping, PetakaG3 FLAT. | 25 pcs box. Sterile |
| Petaka®G3 FLAT, box 300 pcs | FLPTK300 | 1. Petaka CELL CULTURE, 2. Petaka cell shipping, PetakaG3 FLAT. | 300 pcs box. Sterile (SAL 10-6) |
| Petaka®G3 LOT, box 25 pcs | LTPTK25 | 1. Petaka CELL CULTURE, 2. Petaka cell shipping, PetakaG3 LOT. | 25 unit Box Sterile (SAL 10-6) |
| Petaka®G3 LOT, box 300 pcs | LTPTK300 | 1. Petaka CELL CULTURE, 2. Petaka cell shipping, PetakaG3 LOT. | 300 pcs box. Sterile (SAL 10-6) |
| Basic Kit Petaka™G3 FLAT | BK03 | 3. Special Kits. | 3. Special Kits. |
| Basic Kit Petaka™G3 HOT | BKO1 | 3. Special Kits. | - |
| Basic Kit Petaka™G3 LOT | BKO2 | 3. Special Kits. | - |
| Live Cell Monolayer SHIPPING Kit (LOT) | SHPLT | 2. Petaka cell shipping, 3. Special Kits. | - |
| Live Cells in Suspension SHIPPING Kit (FLAT) | SHPFL | 2. Petaka cell shipping, 3. Special Kits. | - |
| Trial Kit Petaka™G3 FLAT | TRAIFT | 3. Special Kits. | - |
| Trial Kit Petaka™G3 HOT | TRAIHT | 3. Special Kits. | - |
| Trial Kit Petaka™G3 LOT | TRAILT | 3. Special Kits. | - |
| Petaka® Mailer, 10 pcs/pack | MAPTK10 | 4. Accessories. | - |
| Stands Petaka®G3, box 12 pcs | - | 4. Accessories. | 12 pcs box |
| Tips, Luer-lock liquid dispensing blunt tips, 100 pcs | TIPM100 | 4. Accessories. | - |
| Petaka G3 DO sensor & thermometer LOT, box 25 pcs Special Order | DOTPTKL-25 | 5. Oxygen measurement | 25pcs box |
| Petaka®G3 DO sensor & thermometer FLAT, box 25 pcs – Special Order | DOTPTKF -25 | 5. Oxygen measurement | 25pcs box |
| Petaka®G3 DO sensor & thermometer FLAT, box 5 pcs – Special Order | DOTPTKF-5 | 5. Oxygen measurement | 5 pcs box |
| Petaka®G3 DO sensor & thermometer LOT, box 5 pcs – Special Order | DOTPTKL-5 | 5. Oxygen measurement | 5 pcs box |
| Petaka®G3 DO sensor FLAT, box 25 pcs – Special Order | DOPTKF-25 | 5. Oxygen measurement | 25 pcs box |
| Petaka®G3 DO sensor FLAT, box 5 pcs | DOPTKF-5 | 5. Oxygen measurement | 5 pcs box |
| Petaka®G3 DO sensor LOT, 25 pcs box – Special Order | DOPTKL-25 | 5. Oxygen measurement | 25pcs box |
| Petaka®G3 DO sensor LOT, 5 pcs box | DOPTKL-5 | 5. Oxygen measurement | 5 pcs box |
| Magnetic ET Driver | MAGPICK | 6. Petaka G3 ET: Easy Transfer. | - |
| Petaka®G3 ET HOT, box 25 pcs | HTPTKET25 | 6. Petaka G3 ET: Easy Transfer. | 25pcs box |
| Petaka®G3 ET LOT, 25 pcs box | LTPTKET25 | 6. Petaka G3 ET: Easy Transfer. | 25 pcs box |
| Petaka™G3 Centrifuge | CENPTK21 | 7. Petaka G3 equipment. | - |
| Programmable Liquid Dispenser Peristaltic Pump Special Order | PPUMP | 7. Petaka G3 equipment. | - |
| Tubing, Valves & Connectors, Replacement Kit for Programmable 150 DP Dispenser Pump | PPUA2 | 7. Petaka G3 equipment. | - |

Zedira是一家临床阶段的生物技术公司,专门从事转谷氨酰胺酶的研究,开发一系列小分子药物候选物。Zedira公司正致力于药物发现的前沿领域,该领域涉及阻止调节失调的转谷氨酰胺酶的小分子。此外,Zedira是一个全球品牌,专门用于转谷氨酰胺酶领域的研发和诊断试剂,其独特和高质量的产品有助于推动转谷氨酰胺酶的研究和应用。
Zedira is a clinical stage biotech company specialised in transglutaminase. Zedira conducts its own development of small molecular drug candidates. In doing so, the company is working at the cutting edge of drug discovery involving small molecules that block dysregulated transglutaminases. In addition, Zedira is a global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. Numerous unique and high quality products help pushing forward transglutaminase-related science – both in academia and industry.
Zedira公司主要产品:
Transglutaminases
Microbial Transglutaminase
Assays and Substrates
Inhibitors
Antibodies and Microarrays
Proteases
Protein Labeling
Blood Coagulation
Cereal Proteins
Celiac Disease Products
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
Zedira产品详情请咨询我司客服人员:
| 产品编号 | 产品名称 | 产品规格 |
| A003 | Polyclonal antibody to human tissue transglutaminase (TG2) | 100 ug |
| A004 | Monoclonal antibody to tissue transglutaminase (TG2) | 100 ug |
| A008 | Polyclonal antibody to human transglutaminase 5 (TG5) | 500 ug |
| A011 | Monoclonal antibody to gliadin (clone XGY1) | 1 mg |
| A013 | Monoclonal antibody to gliadin (clone XGY7) | 1 mg |
| A014 | Polyclonal antibody to human tissue transglutaminase (TG2) | 500 ug |
| A015 | Polyclonal antibody to human epidermal transglutaminase (TG3) | 500 ug |
| A016 | Polyclonal antibody to human blood coagulation factor XIII (A-subunit) | 500 ug |
| A017 | Polyclonal antibody to human neuronal transglutaminase (TG6) | 500 ug |
| A018 | Polyclonal antibody to human keratinocyte transglutaminase (TGI) | 500 ug |
| A020 | Polyclonal antibody to microbial protransglutaminase (pro-MTG, pro-BTG) | 500 ug |
| A021 | Polyclonal antibody to human plasminogen (rhPLG) | 500 ug |
| A022 | Polyclonal antibody to human prostate transglutaminase (TG4) | 500 ug |
| A023 | Monoclonal antibody to N'-ly-L-glutamylpL-lysine-isopeptide bond | 100 ug |
| A024 | Monoclonal Antibody to microbial (bacterial) Transglutaminase | 100 ug |
| A028 | FITC-labeled polyclonal antibody to human TG2 | 200 ug |
| A029 | FITC-labeled polyclonal antibody to human TGI | 200 ug |
| A030 | FITC-labeled polyclonal antibody to human TG3 | 200 ug |
| A031 | FITC-labeled polyclonal antibody to human TG6 | 200 ug |
| A032 | FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 ug |
| A033 | Monoclonal antibody to human TG2 (Catalytic Domain, clone XTG17) | 200 ug |
| A034 | Monoclonal antibody to human TG2 (Beta Sheet Domain, clone XTG 1 1) | 200 ug |
| A035 | Monoclonal antibodies to gliadin (Set No 1) | 1 Set |
| A036 | Monoclonal antibody to human TG2 (Beta Barrel 1 Domain, clone XTG21) | 200 ug |
| A037 | Monoclonal antibody to human TG2 (Beta Barrel 2 Domain, clone XTG1 8) | 200 ug |
| A040 | Polyclonal antibody to human transglutaminase 7 (TG7) | 200 ug |
| A042 | Monoclonal antibody to human TGI (clone XTG3 1) | 200 ug |
| A044 | FITC-labeled polyclonal antibody to human TG5 | 200 ug |
| A046 | D-Dimer monoclonal mouse antibody, clone 3B6 | 100 ug |
| A047 | D-Dimer monoclonal mouse antibody, clone 1 D2 | 100 ug |
| A051 | Biotinylated polyclonal antibody to microbial transglutaminase (MTG) | 50 ug |
| A052 | Biotinylated polyclonal antibody to human factor XIII (A-subunit) | 50 ug |
| A053 | Biotinylated polyclonal antibody to human TG2 | 50 ug |
| A054 | Monoclonal antibody to gliadin (clone XGY6) | 1 mg |
| A057 | Monoclonal antibody to deamidated gliadin | 100 ug |
| A058 | Monoclonal antibody to gliadin (clone XGY5) | 1 mg |
| A059 | Monoclonal antibody to gliadin (clone XGY9) | 1 mg |
| A060 | Monoclonal antibody to gliadin (clone XGY10) | 1 mg |
| A061 | Monoclonal antibody to gliadin (clone XGY 1 6) | 1 mg |
| A062 | Monoclonal antibody to deamidated and non-deamidated gliadin | 100 ug |
| A063 | Monoclonal antibody to gliadin (clone XGY2) | 1 mg |
| A064 | Monoclonal antibody to gliadin (clone XGY4) | 1 mg |
| A065 | Monoclonal antibody to gliadin (clone XGY8) | 1 mg |
| A066 | Monoclonal antibody to gliadin (clone XGY 1 2) | 1 mg |
| A067 | Monoclonal antibody to gliadin (clone XGY 1 5) | 1 mg |
| A068 | Monoclonal antibody to gliadin (clone XGY 1 7) | 1 mg |
| A069 | Monoclonal antibody to gliadin (clone XGY23) | 1 mg |
| A070 | Monoclonal antibody to gliadin (clone XGY24) | 1 mg |
| A071 | Monoclonal antibody to hordein (clone XH4) | 1 mg |
| A072 | polyclonal antibody to mouse tissue Transglutaminse | 200 ug |
| A074 | Polyclonal antibody to human blood coagulation factor XIII (B-subunit) | 200 ug |
| A075 | FITC-labeled polyclonal antibody to mouse TG2 | 200 ug |
| A076 | DD-XLink-mab | 100 ug |
| A077 | FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 ug |
| A078 | Polyclonal antibody to human epidermal transglutaminase (TG3) Protein A | 250 ug |
| A079 | Biotin-DD-XLink-mab | 50 ug |
| A082 | Monoclonal antibody to human TG3 (clone XTG45) | 200 ug |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg |
| A102 | TG2-Assay Substance. Abz-APE(CAD-DNP)QEA-OH | 10 mg |
| A105 | NQEQVSPLTLLK, alpha2-Antiplasmin peptide (1-12) | 25 mg |
| A106 | (ATTO-48 8TM)cadaveri ne | 1 mg |
| A108 | Ac-(D)-Asp-MA-N le-Nle-Leu-Pro-Trp-Pro-OH | 5 mg |
| A109 | β-Amyloid peptide 1-42 (Aβ 1-42) | 1 mg |
| A112 | (ATTO-532)cadaverine | 1 mg |
| A113 | (ATTO-550)cadaverine | 1 mg |
| A114 | (AnO-647N)cadaverine | 1 mg |
| A115 | (ATTO-700)cadaverme | 1 mg |
| A125 | Factor XIII activation peptide | 10 mg |
| A132 | Ac-WALQRPHYSYPD | 10 mg |
| A139 | Monoclonal antibody to human TG6 (Catalytic Domain, clone XTG52) | 200 ug |
| A140 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG39) | 200 ug |
| A141 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG68) | 200 ug |
| A142 | Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG57) | 200 ug |
| A143 | Monoclonal antibody to microbial Transglutaminase (clone XM67) | 200 ug |
| A144 | Monoclonal antibody to microbial Transglutaminase (clone XM68) | 200 ug |
| A145 | Polyclonal Antibody to microbial Transglutaminase | 200 ug |
| A152 | 3-Azido-l -propanamine | 100 mg |
| A153 | 4-Azidobutan-l-amine | 100 mg |
| A154 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) | 200 ug |
| A155 | Monoclonal antibody to human factor XIII (Catalytic Domain, clone XTG02) | 200 ug |
| B001 | Biotinyl-Thr-Val-GIn-GIn-Glu-Leu-OH | 5 mg 25 mg |
| B002 | N-(Biotinyl)cadaverine | 25 mg 100 mg |
| B003 | Boc-DON-Gln-lle-Val-OMez "Boc-DON” | 10 mg |
| B006 | Thr-Val-Gln-Gln-Glu-Leu-OH | 25 mg |
| B007 | Keratinocyte transglutaminase (TGI )-substrate-peptide K5 | 10 mg |
| B008 | Tissue transglutaminase (TG2)-substrate-peptide T26 | 10 mg |
| B009 | Epidermal transglutaminase (TG3)-substrate-peptide E51 | 10 mg |
| B010 | Blood coagulation FXIII-substrate-peptide Fl 1 KA | 10 mg |
| B013 | Neuronal transglutaminase (TG6)-substrate peptide Y25 | 10 mg |
| B014 | Transglutaminase 7 (TG7)-substrate peptide Z3S | 10 mg |
| B015 | Biotin-Ahx-MA-QPL-OMe | 10 mg |
| B017 | Microbial Transglutaminase (MTG)-substrate peptide M48 | 10 mg |
| B019 | Biotin-Ahx-QVPL-OMe | 10 mg |
| C001 | Z-GIn-Gly-OH | 1g |
| C002 | Z-GIn-Gly-CAD-DNS | 25 mg 100 mg |
| C074 | Z-Gln-Gly-CAD-(AnO-488) | 1 mg |
| C075 | Z-Gln-Gly-CAD-(ATTO-532) | 1 mg |
| C076 | Z-Gln-Gly-CAD-(AnO-550) | 1 mg |
| C077 | Z-Gln-Gly-CAD-(ATTO-647N) | 1 mg |
| C078 | Z-Gln-Gly-CAD-(AnO-700) | 1 mg |
| C079 | Z-GIn-Gly-PEG(3)-N3 | 25 mg |
| C080 | Z-Gln-Gly-PEG(11)-N3 | 25 mg |
| C090 | Z-GIn-Gly-CAD-TAMRA | 25 mg |
| C091 | Z-GIn-Gly-CAD-Biotin | 25 mg |
| C092 | Z-Gln-Gly-(PEG1,088), monodisperse | 25 mg |
| C093 | Z-Gln-Gly-(PEG5,000), polydisperse | 25 mg |
| C094 | Tosyl-ε-aminopentyl-CMK | 1 mg |
| C095 | Dansyl-ε-aminopentyl-CMK | 1 mg |
| C102 | MTG Blocker | 10 mg 25 mg |
| D001 | Dansyl-ε-aminohexanoyl-GIn-GIn-lle-Val-OH | 25 mg 100 mg |
| D002 | N-(2,4-Dinitrophenyl)cadaverine | 100 mg |
| D003 | 1,3-Dimethyl-2[(2-oxo-propyl)thio]imidazolium chloride | 100 mg |
| D004 | 1,3-Dimelhyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium | 10 mg |
| D005 | Metalloprotease-Assay-Substance, DABCYL-Ser-Phe-EDANS | 2 mg |
| D006 | N-(Dansyl)cadaverine | 100 mg |
| D007 | Cadaverine | 100 mg |
| D008 | "DALP", DNP-aminohexanoic acid-Lys-aminopropanol | 5 mg |
| D009 | DALP-methyl carbamate | 5 mg |
| D0I 6 | LDN 27219 | 10 mg |
| E018 | ZediXclusive Tissue Transglutaminase EIA | 1 Kit |
| E021 | ZediXclusive Microbial Transglutaminase (MTG) ELISA | 1 Kit |
| E103 | ZediXclusive TG6-ab ELISA (IgA) | 1 Kit (96 wells) |
| E104 | ZediXclusive TG6-ab ELISA (IgG) | 1 Kit (96 wells) |
| F001 | FXIII-Assay Kit | 1 Kit |
| F002 | Tissue Transglutaminase Assay Kit | 1 Kit |
| F004 | Fibrinogen, purified from human plasma | 50 mg |
| F006 | FITC-labeled Fibrinogen | 5 mg |
| F007 | Fibrin Glue (porcine) | 1 Kit |
| F008 | Fibrin Glue (bovine) | 1 Kit |
| F011 | Cross-linked fibrin degradation products, xFDPs | 200 ug |
| F012 | Fibrin degradation products, FDPs | 200 ug |
| G001 | Alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G002 | Deamidated alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G003 | Ac-PLQPEQPFPK(ε-Biotin), Deamidated gliodin peptide | 10 mg |
| G004 | Ac-PEQLPQFEEK(ε-Biotin), Deamidated gliadin peptide | 10 mg |
| G005 | DGPx4 (Fusion protein of 4 deamidated gliadin peptides) | 500 ug |
| G006 | DGPx2 (Fusion protein of 2 deamidated gliadin peptides) | 500 ug |
| G007 | DGPxl (deamidated gliadin peptide) | 500 ug |
| G008 | Omega-5 gliadin | 500 ug |
| G009 | Alpha2-gliadin, 33mer (aa 56-88) | 5 mg |
| G011 | Deamidated alpha2-gliadin, 33mer, (Acetyl-aa56-88-amide, Q65E) | 5 mg |
| G013 | QPFPQPQLPYPQPQ-amide | 10 mg |
| G014 | QPFPQPELPYPQPQ-amide | 10 mg |
| G017 | Biotinylated DGPx1 | 100 ug |
| G018 | Barley albumin and globulin | 5 mg |
| G019 | Barley prolamin (Hordein) | 5 mg |
| G020 | Barley glutelin (Hordenin) | 5 mg |
| G021 | Rye albumin and globulin | 5 mg |
| G022 | Rye prolamin (Secalin) | 5 mg |
| G023 | Rye glutelin (Secalinin) | 5 mg |
| G024 | Corn albumin and globulin | 5 mg |
| G025 | Corn prolamin (Zein) | 5 mg |
| G026 | Corn glutelin (Zeanin) | 5 mg |
| G027 | Rice albumin and globulin | 5 mg |
| G028 | Rice prolamin (Oryzin) | 5 mg |
| G029 | Rice glutelin (Oryzenin) | 5 mg |
| G030 | Spell albumin and globulin | 5 mg |
| G031 | Spelt prolamin | 5 mg |
| G032 | Spelt glutelin | 5 mg |
| G033 | Oat albumin and globulin | 5 mg |
| G034 | Oat prolamin (Avenin) | 5 mg |
| G035 | Oat glutelin (Avenalin) | 5 mg |
| G036 | Wheat albumin and globulin (Leukosin and Edestin) | 5 mg |
| G037 | Wheat prolamin (Gliadin) | 5 mg |
| G038 | Wheat glutelin (Glutenin) | 5 mg |
| G039 | Durum wheat albumin and globulin | 5 mg |
| G040 | Durum wheat prolamin | 5 mg |
| G041 | Durum wheat glutelin | 5 mg |
| G042 | Soy protein, saline soluble fraction | 5 mg |
| G043 | Soy protein, ethanol soluble fraction | 5 mg |
| G044 | Soy protein, propanol/urea/DTE soluble fraction | 5 mg |
| G045 | Millet (Sorghum) albumin and globulin | 5 mg |
| G046 | Millet (Sorghum) prolamin (Kafirin) | 5 mg |
| G047 | Millet (Sorghum) glutelin | 5 mg |
| G048 | L-Glutamic acid γ-monohydroxamate | 100 mg |
| G051 | 26mer gliadin peptide | 250 ug |
| G052 | 33mer gliadin peptide | 250 ug |
| G054 | 33mer DGP | 250 ug |
| G055 | Carrier protein control | 250 ug |
| G056 | DGP and Gliadin peptides (Set No 1) | 1 Set |
| G057 | Alpha2-gliadin, 33mer (aa56-88), TAMRA labeled | 5 mg |
| G058 | Alpha2-gliadin, 33mer (aa56-88), TAMRA and Biotin labeled | 5 mg |
| G101 | Gly-Pro-Arg-Pro-amide | 25 mg |
| I001 | Involucrme, recombinant human | 500 ug |
| K004 | "KxD", Boc-Lys-en-DNS | 10 mg |
| L001 | Substrate Finder Kit | 1 Kit |
| L101 | Biotin TGase Protein Q-Labeling Kit | 1 Kit |
| L102 | PEG1,088 TGase Protein Q-Labeling Kit | 1 Kit |
| L103 | PEG5,000 TGase Protein Q-Labeling Kit | 1 kit |
| L104 | ATTO-488™ TGase Protein Q-Labeling Kit | 1 Kit |
| L105 | ATTO-532™ TGase Protein Q-Labeling Kit | 1 Kit |
| L106 | ATTO-550™ TGase Protein Q-Labeling Kit | 1 Kit |
| L107 | ATTO-647N™ TGase Protein Q-Labeling Kit | 1 Kit |
| L108 | ATTO-700™ TGase Protein Q-Labeling Kit | 1 Kit |
| L201 | Biotin TGase Protein K-Labeling Kit | 1 Kit |
| L202 | PEG1,088 TGase Protein K-Labeling Kit | 1 Kit |
| L203 | PEG5,000 TGase Protein K-Labeling Kit | 1 Kit |
| L204 | ATTO-488™ TGase Protein K-Labeling Kit | 1 Kit |
| L205 | ATTO-532™ TGase Protein K-Labeling Kit | 1 Kit |
| L206 | ATTO-550™ TGase Protein K-Labeling Kit | 1 Kit |
| L207 | ATTO-647N™ TGase Protein K-Labeling Kit | 1 Kit |
| L208 | ATTO-700™ TGase Protein K-Labeling Kit | 1 Kit |
| M001 | MTG-ANiTA-Kit | 1 Kit |
| M003 | Tissue Transglutaminase Pico-Assay Kit | 1 Kit |
| P003 | Prolylendopeptidase from Myxococcus xanthus, recombinant | 150U |
| P004 | PT-Gluten | 1 mg 10 mg |
| P009 | human Pro-Glu-Plasminogen, recombinant | 100 ug |
| P010 | (PEG1,088)amine, monodisperse | 10 mg |
| P011 | (PEG5,000)amine, polydisperse | 10 mg |
| P012 | human Plasmin, recombinant | 100 ug |
| P0U | Urokinase | 1 mg |
| P015 | Streptokinase (bacterial plasminogen activator) | 1 mg |
| P016 | Tissue Plasminogen Activator | 100 ug |
| P111 | PEPperCHIP Pan-Transglutaminase Microarray | 1 Chip |
| P112 | PEPperCHIP Custom Transglutaminase Microarray | 1 Chip |
| P113 | PEPperCHIP Transglutaminase Microarray Service | 1 Sample |
| P114 | PepSlide Analyzer | 3-Month/1-Year/Perpetual License |
| P115 | PEPperCHIP Incubation Tray 3/1 | 1 Tray |
| P116 | PEPperCHIP Staining Kit | 1 Kit |
| P117 | PEPperCHIP Transglutaminase 2 Microarray | 1 Chip |
| P118 | PEPperCHIP Incubation Tray 3/5 | 1 Tray |
| R001 | N-(Tetrametylrhodaminyl)cadaverine | 10 mg |
| R002 | TAMRA-DON | 5 mg 10 mg |
| T001 | Microbial (bacterial) transglutaminase | 25 U; 1 x 250 U;10x 25 U; lx 500 U; 20x 25 U |
| T002 | Human tissue transglutaminase (TG2) | 250 ug 1mg |
| T004 | N-(p-Tosyl)-Gly-Pro-Lys-pNA | 25 mg |
| T006 | Guinea pig liver transglutaminase | 10U |
| T009 | Human keratinocyte transglutaminase (TG1) | 150 ug |
| T011 | Human transglutaminase 7 | 250 ug |
| T013 | Human epidermal transglutaminase, Dispose activated | 200 ug |
| T016 | Microbial (bacterial) Pro-transglutaminase | 250 ug |
| T018 | Inactive human tissue transglutaminase | 250 ug 1 mg |
| T021 | Human neuronal transglutaminase (TG6) | 250 ug |
| T022 | Human tissue transglutaminase (TG2) | 250 ug 1 mg |
| T024 | Human epidermal transglutaminase (TG3) | 200 ug |
| T027 | Human blood coagulation Factor Xlll-A z recombinant | 200 ug |
| T034 | Human tissue transglutaminase (TG2) | 100 ug |
| T035 | Human keratinocyte transglutaminase (TGI) | 150 ug |
| T036 | Transglutaminase Assay Kit, fluorescent, Casein, Dansylcadaverine | 1 Kit |
| T038 | Rat tissue transglutaminase | 250 ug 1 mg |
| T039 | Guinea pig liver transglutaminase, recombinant | 10U |
| T040 | Mouse tissue transglutaminase | 250 ug 1 mg |
| T042 | Human prostate Transglutaminase (TG4) | 100 ug |
| T050 | Human blood coagulation Factor XIII B subunit | 200 ug |
| T051 | Open tTG™ | 250 ug |
| T055 | Tissue Transglutaminase Microassay Kit, colorimetric | 1 Kit |
| T056 | Human alpha thrombin, highly active | 200 U |
| T057 | Inhibited human epidermal transglutaminase | 250 ug |
| T061 | Mouse blood coagulation Factor Xlll-A2 | 200 ug |
| T062 | Dog blood coagulation Factor Xlll-A2 | 200 ug |
| T063 | Human blood coagulation Factor Xlll-A2 , Val34Leu-mutant | 200 ug |
| T064 | Inhibited human neuronal transglutaminase | 250 ug |
| T065 | Rat blood coagulation Factor Xlll-A2 | 200 ug |
| T066 | Pig blood coagulation Factor Xlll-A2 | 200 ug |
| T067 | Human tissue transglutaminase (TG2), endotoxin free | 250 ug 1 mg |
| T070 | Human Factor Xllla, Thrombin activated | 200 ug |
| T072 | Dog tissue transglutaminase | 250 ug 1 mg |
| T086 | Human Transglutaminase 5 | 100 ug |
| T087 | Tridegin | 200 ug |
| T092 | Human blood coagulation Factor Xlll-A2 | 100 ug |
| T101 | 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg |
| T102 | Mouse Open TG2 | 250 ug 1 mg |
| T106 | Biotinylated human tissue transglutaminase (TG2) | 100 ug 250 ug |
| T108 | Cynomolgus tissue transglutaminase | 250 ug |
| T109 | Cynomolgus open TG2 | 100 ug |
| T1 10 | Recombinant TG2 [E.coli] | 500 ug |
| T1 14 | Blood Coagulation Factor Xlll-Microassay Kit, colorimetric | 1 Kit |
| T117 | Biotinylated inactive hTG2 (Cys277Ser) | 250 ug 1 mg |
| T122 | Recombinant TG2 (insect cells) | 500 ug |
| T123 | Biotinylated human tissue transglutaminase (TG2) | 50 ug |
| T124 | Recombinant TG3 (insect cells) | 400 ug |
| T127 | Biotinylated human blood coagulation Factor XIII | 50 ug |
| T134 | Open tTG™ | 100 ug |
| T139 | Rabbit tissue transglutaminase | 250 ug 1mg |
| T140 | Biotinylated human epidermal transglutaminase | 100 ug |
| T141 | Biotinylated human neuronal transglutaminase | 100 ug |
| T142 | Biotinylated mouse blood coagulation Factor Xlll-A2 | 50 ug |
| T146 | Mouse neuronal transglutaminase | 250 ug |
| T148 | Biotinylated human Open tTG™ | 50 ug 1 mg |
| T149 | Oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T150 | Biotinylated mouse open TG2 | 50 ug |
| T151 | Biotinylated oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T152 | Rabbit blood coagulation Factor Xlll-A2 | 200 ug |
| T153 | Microbial (bacterial) transglutaminase, edotoxin free | 25 U;10x 25 U;20x 25 U |
| T156 | Biotinylated mouse tissue transglutaminase | 250 ug; 1 mg |
| T159 | Pig tissue transglutaminase | 250 ug; 1 mg |
| T160 | Biotinylated cynomolgus tissue transglutaminase | 50 ug |
| T161 | Cynomolgus blood coagulation Factor Xlll-A2 | 200 ug |
| T167 | Short human tissue transglutaminase, aa 1-475 | 250 ug |
| T168 | Human tissue transglutaminase, C23OA mutant | 250 ug;1 mg |
| T169 | Human tissue transglutaminase, R580A mutant | 250 ug;1 mg |
| T173 | Human tissue transglutaminase, R116C mutant | 1 mg |
| T178 | Microbial transglutaminase with C-terminal His6-tag | 25 U;10 x 25 U;20 x 25 U |
| T184 | Cat tissue transglutaminase | 200 ug |
| T187 | Factor XIII activation peptide, recombinant | 500 ug |
| T197 | Coagulation factor XIII, recombinant human Factor Xlll-A2 | 100E;250E |
| T222 | Human alpha Thrombin, recombinant | 100 NIH Units |
| Z004 | Z-Gln-GIn-Pro-Leu-OH | 25 mg |
| Z006 | Z-DON-Val-Pro-Leu-OMe,"Z-DON" | 10 mg |
| Z009 | ZediXclusive Microbial Transglutaminase Assay Kit | 1 Kit |
| Z010 | ZediXclusive Tissue Transglutaminase Assay Kit | 1 Kit |
| Z011 | Z-(D)-DON-Val-Pro-Leu-OMe | 10 mg |
| Z013 | Z-MA-QPL-OMe | 10 mg |
| Z015 | Keillor inhibitor AA9 | 10 mg |
| Z016 | Keillor inhibitor NC9 | 10 mg |
| Z017 | Keillor inhibitor VA4 | 10 mg |

艾美捷科技代理VisualProtein品牌。
VisualProtein成立于2005年,致力于通过提供创新的科研产品与服务推动生物领域发展。凭借在蛋白质组学、免疫学及细胞学领域的专业深耕,不断拓宽科学研究的可能性边界。
Visual Protein的产品包括:
| 分类 | 品名 | 货号 |
| Proteomics | Western Blot Tool Box | BOX12 |
| Proteomics | Western Blot Tool Box with LuminolPen(LH03-10) | BOX12-03 |
| Proteomics | BlockPRO™ Blocking Buffer | BP01-1L |
| Proteomics | BlockPRO™ Protein-Free Blocking Buffer | BF01 |
| Proteomics | BlockPRO™ 1 Min Protein-Free Blocking Buffer | BM01 |
| Proteomics | LuminolPen™, HRP system | LH03 |
| Proteomics | LumiFlash™ Prime Chemiluminescent Substrate, HRP System | LF01-500 |
| Proteomics | LumiFlash™ Ultima Chemiluminescent Substrate, HRP System | LF08-500 |
| Proteomics | LumiFlash™ Infinity Chemiluminescent Substrate, HRP System | LF16-500 |
| Proteomics | LumiFlash™ Femto Chemiluminescent substrate, HRP System | LF24-100 |
| Proteomics | ExtractPRO™ Protein Extraction Reagent | EP05-30 |
| Proteomics | RIPA Cell Lysis Buffer | RP05 |
| Proteomics | Dual-Range™ BCA Protein Assay Kit | BC03-500 |
| Proteomics | Dual-Range™ Bradford Reagent (1X) | BR01-500 |
| Proteomics | Dual-Range™ Bradford Reagent (5X) | BR05-500 |
| Proteomics | Dual-Range™ Bradford Protein Assay Kit (5X) | BR05-500-K |
| Proteomics | VisPRO™ Blue-One Protein Stain | VB01-500 |
| Proteomics | VisPRO™ 5 Minute Protein Stain Kit | VP01 |
| Proteomics | 6X Laemmli SDS Sample Buffer, non-reducing(without beta-mercaptoethanol) | SBN06-15 |
| Proteomics | 6X Laemmli SDS Sample Buffer, reducing(with beta-mercaptoethanol) | SBR06-15 |
| Immunoassay buffer | ImmunoEX immunoassayDevelopment Kit(TBST) | IEX001 |
| Immunoassay buffer | ImmunoEX ImmunoassayDevelopment Kit (TBS) | IEX002 |
| Immunoassay buffer | ImmunoEX TBST Buffer | IE01-500 |
| Immunoassay buffer | ImmunoEX TBS Buffer | IE02-500 |
| Immunoassay buffer | mmunoEX Protein-BasedImmunoassay Buffer(TBST | IE03-500 |
| Immunoassay buffer | ImmunoEX Protein-Based lmmunoassay Buffer (TBS) | IE04-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer(TBST | IE05-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer (TBS) | IE06-500 |
| Supplement | CytoMore Cell RescueSupplement | CTO1-1BT |
| Supplement | HybriMore™ Hybridoma Culture Supplement* | HB01-1L |
| Buffer | PBS Buffer, 10X | PBS10-1L |
| Buffer | PBS Tween-20 Buffer, 10X | PBST10-1L |
| Buffer | TBS Buffer, 10X | TBS10-1L |
| Buffer | TBS Tween-20 Buffer, 10X | TBST10-1L |
| Buffer | TBS Tween-20 Buffer, 25X | TBST200P |
| Buffer | SDS-PAGE Running Buffer, 10X | RB10-1L |
| Buffer | SDS-PAGE Running Buffer, powder pack | RB500P |
| Buffer | Western Blot Transfer Buffer, 10X | WTB10-1L |
| Buffer | Western Blot Transfer Buffer, powder pack | WTB500P |
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理VisualProtein品牌"> 艾美捷科技代理VisualProtein品牌
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:18771149750
邮箱:sales@amyjet.com
0.1494